Evolution of Patient-Reported Outcomes and Their Role in Multiple Sclerosis Clinical Trials.

ABSTRACT: Patient-reported outcomes (PROs) are playing an increasing role in multiple sclerosis (MS) research and practice, and are essential for understanding the effects that MS and MS treatments have on patients' lives. PROs are captured directly from patients and include symptoms, function, health status, and health-related quality of life. In this article, we review different categories (e.g., generic, targeted, preference-based) of PRO measures and considerations in selecting a measure. The PROs included in MS clinical research have evolved over time, as have the measures used to assess them. We describe findings from recent MS clinical trials that included PROs when evaluating Food and Drug Administration-approved disease-modifying therapies (e.g., daclizumab, teriflunomide). Variation in the

SUBMITTER: Nowinski CJ 

PROVIDER: S-EPMC5722775 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature